Dyne Therapeutics CEO and President John Cox sold 5,658 shares at $18.88 per share on Sep. 8, 2026. Cox retained 357,507 shares after the transaction, giving investors the reported ownership figure for the company’s chief executive following the sale.
Key Highlights
- Dyne Therapeutics CEO and President John Cox held 357,507 shares after the transaction.
- The sale was recorded under transaction code S.
- Cox completed the transaction on Sep. 8, 2026.
Dyne Therapeutics, Inc. (NASDAQ: DYN) CEO and President John Cox sold 5,658 shares at $18.88 per share on Sep. 8, 2026. The transaction left Cox with 357,507 shares.
John Cox’s 5,658-Share Transaction
The sale was recorded under transaction code S. Cox’s position following the transaction was 357,507 shares of Dyne Therapeutics, Inc. The reported sale involved 5,658 shares, with each share priced at $18.88. Cox’s role at Dyne Therapeutics is CEO and President. The transaction date was Sep. 8, 2026. The reported post-transaction holding was measured after the sale had taken place. The per-share price was $18.88. The number of shares sold was 5,658. Cox’s resulting ownership was 357,507 shares.
FAQs
Q: How many Dyne Therapeutics shares did John Cox sell?
A: Dyne Therapeutics CEO and President John Cox sold 5,658 shares in the reported transaction. The filing states that each share was sold at a price of $18.88.
Q: What was John Cox’s remaining Dyne Therapeutics holding?
A: Following the transaction, John Cox owned 357,507 shares of Dyne Therapeutics. This was the reported post-transaction holding after the sale of 5,658 shares.
Q: When did the Dyne Therapeutics insider sale occur?
A: John Cox completed the Dyne Therapeutics share sale on Sep. 8, 2026. The transaction involved 5,658 shares and was recorded under transaction code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.